To include your compound in the COVID-19 Resource Center, submit it here.

Stressing out cancer

Quentis launches from Glimcher lab with $48M to target ER stress in cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells in the tumor microenvironment.

The company is based on findings from the lab of Laurie Glimcher, president and CEO of Dana-Farber Cancer Institute, who is a co-founder of the

Read the full 649 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers